JAX GUIDE: Assessing antibody pharmacokinetics using the FcRn platform from JAX

The preclinical development of antibodies poses unique challenges. Antibodies, in particular, display a high level of species-specificity not only in target binding through the variable region but also in the Fc region, which is required for extending half-life.

In this application note, The Jackson Laboratory discuss several challenges in developing antibody-based therapeutics, including assessing pharmacokinetic characteristics, selecting efficacious variants, and determining the appropriate dose.